BioSpace News Archive

Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, today announced that John E. Milad, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on July 21-23, 2021.

Genentech, a member of the Roche Group, announced results from the final analysis of the Phase IIIb STASEY study, which confirm the favorable safety profile of Hemlibra®, consistent with the Phase III HAVEN clinical program.

Dermal curettes have shown a promising potential in wide range of dermatologic surgeries, notably in cartilage sculpting tool.

The present and the future scenario of the acupuncture lasers are forecasted to boost the market as there is extreme demand for painless and non-invasive features provided by the medical devices like acupuncture lasers.

During the period July 15, 2021 until July 16, 2021, Vitrolife AB has repurchased a total of 52,568 shares as part of the buyback program introduced by the Board of Directors to secure the obligations of Vitrolife relating to the long-term incentive program LTIP2021.

Takeda Pharmaceutical Company Limited announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange in accordance with the regulations* for TSE listed companies.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the presentation of 14 scientific posters involving the company’s ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting, which will take place from July 23-27, 2021, in Las Vegas.

Oblato, Inc. announced that it has received an agreement from the FDA for its plan to submit an intermediate size expanded access protocol for use of OKN-007 in patients with high-grade gliomas.

ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, announced key appointments to its science leadership: David Proia, Ph.D., as Vice President, Oncology; Menachem Fromer, Ph.D., as Head of Data Science; and Sarah Knutson, Ph.D., as Senior Director, Early Discovery.

CytoSorbents Corporation a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, will report second quarter 2021 operating and financial results after the market close on August 3, 2021.